Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy

International Journal of Oncology

Volumn 48, Issue 3, 2016, Pages 953-964

  Mikyšková, Romana ^a   Štěpánek, Ivan ^a   Indrová, Marie ^a   Bieblová, Jana ^a   Šímová, Jana ^a   Truxová, Iva ^c   Moserová, Irena ^c   Fučíková, Jitka ^b,c   Bartuňková, Jiřina ^b,c   Špíšek, Radek ^b,c   Reiniš, Milan ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^c Sotio   (Czech Republic)

Author keywords

Cancer; Dendritic cells; Docetaxel; High hydrostatic pressure; Immunotherapy

Indexed keywords

B7 ANTIGEN; DENDRITIC CELL VACCINE; DOCETAXEL; GAMMA INTERFERON; INTERLEUKIN 12; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; CANCER VACCINE; TAXOID; TLR9 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 9; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FLUORESCENCE; HYDROSTATIC PRESSURE; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; ANIMAL; C57BL MOUSE; CHEMISTRY; CYTOLOGY; CYTOTOXICITY; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS, EXPERIMENTAL; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; PROSTATIC NEOPLASMS; SPLEEN; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HUMANS; HYDROSTATIC PRESSURE; IMMUNE SYSTEM; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-12; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PAPILLOMAVIRUS INFECTIONS; PROSTATIC NEOPLASMS; SPLEEN; TAXOIDS; TOLL-LIKE RECEPTOR 9;

EID: 84959020402     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3314     Document Type: Article

References (39)

1. Ramakrishnan R, Antonia S and Gabrilovich DI. Combined modality immunotherapy and chemotherapy: A new perspective. Cancer Immunol Immunother 57: 1523-1529, 2008
2. Nowak AK, Lake RA and Robinson BW. Combined chemoimmunotherapy of solid tumours: Improving vaccines? Adv Drug Deliv Rev 58: 975-990, 2006
3. Banchereau J and Steinman RM. Dendritic cells and the control of immunity. Nature 392: 245-252, 1998
4. Palucka K and Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12: 265-277, 2012
5. Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L and Kroemer G. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 1: 1111-1134, 2012
6. Podrazil M, Horvath R, Becht E, Rozkova D, Bilkova P, Sochorova K, Hromadkova H, Kayserova J, Vavrova K, Lastovicka J, et al. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget 6: 18192-18205, 2015
7. Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J and Spísek R. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 71: 4821-4833, 2011
8. Hato SV, Khong A, de Vries IJ and Lesterhuis WJ. Molecular pathways: The immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res 20: 2831-2837, 2014
9. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S and Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: Therapeutic implications. Blood 109: 4839-4845, 2007
10. Galluzzi L, Kepp O and Kroemer G. Immunogenic cell death in radiation therapy. Oncoimmunology 2: e26536, 2013
11. Weiss EM, Frey B, Rödel F, Herrmann M, Schlücker E, Voll RE, Fietkau R and Gaipl US. Ex vivo-And in vivo-induced dead tumor cells as modulators of antitumor responses. Ann NY Acad Sci 1209: 109-117, 2010
12. Frey B, Rubner Y, Kulzer L, Werthmöller N, Weiss EM, Fietkau R and Gaipl US. Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother 63: 29-36, 2014
13. Fucikova J, Moserova I, Truxova I, Hermanova I, Vancurova I, Partlova S, Fialova A, Sojka L, Cartron PF, Houska M, et al. High hydrostatic pressure induces immunogenic cell death in human tumor cells. Int J Cancer 135: 1165-1177, 2014
14. Emens LA. Chemoimmunotherapy. Cancer J 16: 295-303, 2010
15. Ménard C, Martin F, Apetoh L, Bouyer F and Ghiringhelli F. Cancer chemotherapy: Not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 57: 1579-1587, 2008
16. van Dodewaard-de Jong JM, Verheul HM, Bloemendal HJ, de Klerk JM, Carducci MA and van den Eertwegh AJ. New treatment options for patients with metastatic prostate cancer: What is the optimal sequence? Clin Genitourin Cancer 13: 271-279, 2015
17. Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI and Jaffee EM. Cyclophosphamide, doxorubicin and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61: 3689-3697, 2001
18. Malvicini M, Rizzo M, Alaniz L, Piñero F, García M, Atorrasagasti C, Aquino JB, Rozados V, Scharovsky OG, Matar P, et al A novel synergistic combination of cyclophosphamide and gene transfer of interleukin-12 eradicates colorectal carcinoma in mice. Clin Cancer Res 15: 7256-7265, 2009
19. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et al; TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004
20. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520, 2004
21. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al; IMPACT Study Investigators: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422, 2010
22. Reinis M, Indrová M, Mendoza L, Mikysková R, Bieblová J, Bubeník J and Símová J. HPV 16-Associated tumours: Therapy of surgical minimal residual disease with dendritic cell-based vaccines. Int J Oncol 25: 1165-1170, 2004
23. Reinis M, Stepanek I, Simova J, Bieblova J, Pribylova H, Indrova M and Bubenik J. Induction of protective immunity against MHC class I-deficient, HPV16-Associated tumours with peptide and dendritic cell-based vaccines. Int J Oncol 36: 545-551, 2010
24. Indrová M, Reinis M, Bubeník J, Jandlová T, Bieblová J, Vonka V and Velek J. Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects. Folia Biol (Praha) 50: 184-193, 2004
25. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM and Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56: 21-26, 1996
26. Foster BA, Gingrich JR, Kwon ED, Madias C and Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 57: 3325-3330, 1997
27. Lutz MB, Kukutsch N, Ogilvie AL, Rössner S, Koch F, Romani N and Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223: 77-92, 1999
28. Stepanek I, Indrova M, Bieblova J, Fucikova J, Spisek R, Bubenik J and Reinis M. Effects of 5-Azacytidine and trichostatin A on dendritic cell maturation. J Biol Regul Homeost Agents 25: 517-529, 2011
29. Yi AK and Krieg AM. CpG DNA rescue from anti-IgM-induced WEHI-231 B lymphoma apoptosis via modulation of I kappa B alpha and Ikappa B beta and sustained activation of nuclear factor-kappa B/c-Rel. J Immunol 160: 1240-1245, 1998
30. Reinis M, Símová J, Indrová M, Bieblová J, Pribylová H, Moravcová S, Jandlová T and Bubeník J. Immunization with MHC class I-negative but not-positive HPV16-Associated tumour cells inhibits growth of MHC class I-negative tumours. Int J Oncol 30: 1011-1017, 2007
31. Indrová M, Símová J, Bieblová J, Bubeník J and Reinis M. NK 1.1+cells are important for the development of protective immunity against MHC I-deficient, HPV 16-Associated tumours. Oncol Rep 25: 281-288, 2011
32. Bubenik J, Zeuthen J, Indrova M, Bubenikova D and Simova J. Kinetics and function of peritoneal-exudate cells during local IL-2 gene-Therapy of cancer. Int J Oncol 4: 13-16, 1994
33. Indrová M, Mikysková R, Jandlová T, Vonka V, Bubeník J and Bieblová J. Adjuvant cytokine treatment of minimal residual disease after surgical therapy in mice carrying HPV16-Associated tumours: Cytolytic activity of spleen cells from tumour regressors. Folia Biol (Praha) 49: 217-222, 2003
34. Frey B, Janko C, Ebel N, Meister S, Schlücker E, Meyer-Pittroff R, Fietkau R, Herrmann M and Gaipl US. Cells under pressure-Treatment of eukaryotic cells with high hydrostatic pressure, from physiologic aspects to pressure induced cell death. Curr Med Chem 15: 2329-2336, 2008
35. Adkins I, Fucikova J, Garg AD, Agostinis P and Špíšek R. Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology 3: e968434, 2014
36. Martini M, Testi MG, Pasetto M, Picchio MC, Innamorati G, Mazzocco M, Ugel S, Cingarlini S, Bronte V, Zanovello P, et al. IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine 28: 3548-3557, 2010
37. Okamoto M and Sato M. Toll-like receptor signaling in anticancer immunity. J Med Invest 50: 9-24, 2003
38. Reinis M, Símová J, Indrová M, Bieblová J and Bubeník J. CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-Associated tumours. Int J Oncol 30: 1247-1251, 2007
39. Spranger S, Javorovic M, Bürdek M, Wilde S, Mosetter B, Tippmer S, Bigalke I, Geiger C, Schendel DJ and Frankenberger B. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. JImmunol 185: 738-747, 2010